And 3 months later...
There are plenty of examples of drugs being successful second to market. The point I was making is the expected revenues are much less. Look what 3-months did for PD1 inhibitors. For an already small OV market in melanoma, what do you think a 2nd place OV therapy will generate?
Seems I am doing more research into OV therapies than most of the people here. A lot of hope here - let the data tell the story.
Why IMU is a multi multi bagger, page-22297
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $424.5M | |||
| Open | High | Low | Value | Volume |
| 5.8¢ | 5.8¢ | 5.6¢ | $1.032M | 18.08M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 90000 | 5.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.8¢ | 744737 | 5 |
View Market Depth
| Last trade - 16.10pm 14/06/2024 (20 minute delay) ? |
|
|||||
|
Last
5.8¢ |
Change
0.000 ( 1.03 %) |
||||
| Open | High | Low | Volume | ||
| 5.8¢ | 5.8¢ | 5.6¢ | 4924782 | ||
| Last updated 15.59pm 14/06/2024 ? | |||||
| IMU (ASX) Chart |